Columbia University Herbert Irving Comprehensive Cancer Center | Strategic Alliance Partners

Dr Shu discusses updated data from the VISION trial of tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Markus Y. Mapara, MD, PhD, of Columbia University Irving Cancer Center, discusses the use of allogeneic transplant and gene therapy for patients with sickle cell disease.

Nicole Lamanna, MD, shares key considerations for the use of pirtobrutinib in the management of chronic lymphocytic leukemia.

Dr Lamanna discusses how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in CLL.

Benjamin Herzberg, MD, discusses unanswered questions regarding the role of KRAS inhibitors for patients with non–small cell lung cancer.

Benjamin Herzberg, MD, discusses current and future research efforts in KRAS-mutated NSCLC.

Experts from across oncology specialties discuss the long-term effects of the COVID-19 pandemic on patient care.

Benjamin Herzberg, MD, highlights novel therapies in the KRAS-mutated NSCLC landscape and ongoing questions research is seeking to answer in this space.

Benjamin Herzberg, MD, details research in KRAS G12C-mutated NSCLC with divarasib and how he currently selects between available therapies in this space.

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Eric Winer, MD, discusses considerations for inavolisib plus palbociclib with fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.

Jennifer Amengual, MD, discusses the efficacy of tazemetostat plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Jennifer Amengual, MD, discusses real-world outcomes with CAR T-cell therapy and bispecific antibodies in patients with DLBCL.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

Suzanne Lentzsch, MD, PhD, discusses updated data from the LINKER-MM1 study of linvoseltamab in relapsed/refractory multiple myeloma.

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

Hua-Jay “Jeff” Cherng, MD, discusses efficacy and safety considerations for the use of bispecific antibodies in patients with DLBCL.

Linvoseltamab induced durable responses in patients with relapsed or refractory multiple myeloma, including those with high-risk features.

Sunil Iyer, MD, discusses the design of the phase 3 COMMANDS trial in patients with lower-risk myelodysplastic syndrome with anemia.

Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.

Sunil Iyer, MD, expands on the impact of the FDA’s approval of luspatercept on the management of lower-risk myelodysplastic syndrome.

Joseph G. Jurcic, MD, discusses the benefits and limitations of several JAK inhibitors for patients with myelofibrosis.